摘要：SummaryLung cancer is an extremely heterogeneous disease, and its treatment remains one of the most challenging tasks in medicine. Few existing laboratory lung cancer models can faithfully recapitulate the diversity of the disease and predict therapy response. Here, we establish 12 patient-derived organoids from the most common lung cancer subtype, lung adenocarcinoma (LADC). Extensive gene and histopathology profiling show that the tumor organoids retain the histological architectures, genomic landscapes, and gene expression profiles of their parental tumors. Patient-derived lung cancer organoids are amenable for biomarker identification and high-throughput drug screeningin vitro. This study should enable the generation of patient-derived lung cancer organoid lines, which can be used to further the understanding of lung cancer pathophysiology and to assess drug response in personalized medicine.Graphical AbstractDisplay OmittedHighlights•Generation of a living biobank of patient-derived lung adenocarcinoma organoids•Organoid biobank encompasses most of known subtypes of adenocarcinoma•Organoids maintain the histological and mutational spectrum of original tumors•Tumor organoids provide a tool for biomarker identification and drug testingTissue Engineering; Biotechnology; Cancer
